No Data
AIM Vaccine (HKG:6660) Is Making Moderate Use Of Debt
The Nobel Prize was announced in 2024, and the leading nucleic acid drug, Ami Vaccine (06660.HK), outshined others.
Just last night, the highly anticipated 2024 Nobel Prize in Physiology or Medicine was announced globally! Dr. Victor Ambros and Dr. Gary Ruvkun jointly won this award for their discovery of microRNA and its role in post-transcriptional gene regulation. This award is not only a recognition of their individual contributions, but also a significant boost to global biomedical research. At the same time, this marks the second consecutive year that RNA technology has received the Nobel Prize, inspiring domestic pharmaceutical companies focusing on the research and development of nucleic acid drugs such as RNA and mRNA to explore the innovative applications of this cutting-edge technology with even greater determination.
Beneficiary concept stocks of the Nobel Prize in 2024, leading the strong rise of the nucleic acid drug sector.
It is found that many listed companies are involved in the research and development of nucleic acid drugs such as RNA and mRNA, spanning multiple fields including biotechnology, pharmaceuticals, and medical instruments.
AIM Vaccine's Phase 3 Clinical Trial Shows Serum-Free Rabies Vaccine Has Good Safety; Shares Up 15%
[Hong Kong Stock Connect] Amy Vaccine (06660) rose more than 12%. The company's pioneering serum-free rabies vaccine is expected to be launched on the market.
Kingston Financial Newsletter | Aimee Vaccine (06660) fluctuated and rose, as of the deadline, up 12.22%, trading at 12.12 Hong Kong dollars, with a turnover of 20.7654 million Hong Kong dollars. Announced that it recently received a notification from the China Food and Drug Administration Research Institute regarding the serum antibody test results of the Phase III clinical trial of the serum-free iterative rabies vaccine. The relevant clinical trial data have been unblinded and statistically analyzed. The research results show that the serum-free iterative rabies vaccine has good immunogenicity and good safety, achieving the clinical preset goals. The Group stated that it has completed the construction of a production-capable serum-free iterative rabies vaccine.
Express News | Phase III Clinical Data of AIM Vaccine Iterative Serum-Free Rabies Vaccine Reaches Preset Goals
AIM Vaccine Insider Ups Holding By 649% During Year
No Data
No Data
